omniture
KAZIA THERAPEUTICS LIMITED.

Latest News

Board Review of Business Operations and Governance

SYDNEY, Aug. 14, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology ...

2017-08-14 11:02 2705

Progress Update on Cantrixil(TM) (TRXE-002-1) Development

SYDNEY, Aug. 7, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology d...

2017-08-07 11:03 2416

Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformatio...

2017-03-10 09:21 3483

Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

SYDNEY, March 6, 2017 /PRNewswire/ -- * Grant is provided under Cooperative Research Centre Pr...

2017-03-06 18:54 2430

Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma

SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, No...

2016-10-31 11:54 2307

Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma

SYDNEY, Oct. 31, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company, Novog...

2016-10-31 11:40 2025

Conversion of Convertible Notes

SYDNEY, Sept. 14, 2016 /PRNewswire/ -- On 19 April 2013, the shareholders of Novogen Limited approv...

2016-09-14 12:07 2083

US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer

SYDNEY, Sept. 12, 2016 /PRNewswire/ -- * Cantrixil (TRX-E-002-1) is Novogen's lead development c...

2016-09-12 11:00 2229

Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer

SYDNEY, Aug. 11, 2016 /PRNewswire/ -- Australian oncology-focused biotechnology company Nov...

2016-08-11 13:59 2882

Novogen Patent Covering Anisina(TM) Has Proceeded to Grant

SYDNEY, June 14, 2016 /PRNewswire/ -- US-Australian drug discovery company Novogen Ltd (ASX: NRT; N...

2016-06-14 08:30 2494

Novogen Provides Update On Development Of Cantrixil

SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT...

2016-05-02 10:43 2722

Novogen Receives R&D Tax Incentive Cash Refund

SYDNEY, March 17, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:N...

2016-03-17 10:27 2759

Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant

SYDNEY, Feb. 19, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NR...

2016-02-19 14:18 2551

Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed

SYDNEY, Feb. 5, 2016 /PRNewswire/ -- Australian-US drug discovery and development company, No...

2016-02-05 15:31 3178

Novogen Appoints Dr James Garner as Chief Executive Officer

SYDNEY, Dec. 10, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NR...

2015-12-10 06:02 3529

Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial

SYDNEY, Nov. 24, 2015 /PRNewswire/ -- * Novogen engages Novotech as CRO for upcoming Phase 1 cli...

2015-11-24 08:38 2437

Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia

SYDNEY, Nov. 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (...

2015-11-12 08:04 2108

Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina

FORT LAUDERDALE, Fla., Nov. 11, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen ...

2015-11-11 06:40 1668

Novogen Applies for Long-term Options Listing

SYDNEY, Sept. 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: ...

2015-09-30 10:52 2548

Novogen Announces The Outcome Of A Comprehensive Science Review

SYDNEY, Aug. 31, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen ...

2015-08-31 07:00 1968